BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 2,695 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 2,695 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $25.44, for a total transaction of $68,560.80. Following the sale, the insider now directly owns 43,165 shares of the company’s stock, valued at $1,098,117.60. The trade was a 5.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The shares were sold at an average price of $24.96, for a total transaction of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Stock Down 2.3 %

NASDAQ BLFS opened at $25.33 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market capitalization of $1.19 billion, a P/E ratio of -23.90 and a beta of 2.04. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The stock has a 50 day moving average price of $26.53 and a 200-day moving average price of $25.49.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same period in the prior year, the company earned ($0.21) EPS. As a group, equities analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Trading of BioLife Solutions

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in BioLife Solutions by 13.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock valued at $1,835,000 after buying an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in BioLife Solutions during the 4th quarter valued at $31,000. Point72 Asset Management L.P. purchased a new stake in BioLife Solutions during the 4th quarter valued at $11,113,000. ProShare Advisors LLC purchased a new stake in BioLife Solutions in the fourth quarter worth $282,000. Finally, Millennium Management LLC increased its stake in BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after purchasing an additional 377,111 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Benchmark reiterated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. KeyCorp upped their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Northland Securities upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright upped their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.